Braxia Scientific launches Braxia Institute to advance psychiatric practices and health services for ketamine and psychedelic treatment therapy

Braxia Scientific Corp (CSE:BRAX) (OTCMKTS:SHRMF) (FRA:4960) has launched the Braxia Institute, its training Centre of Excellence focused on advancing psychiatric clinical practice and health services of ketamine and psychedelic treatment therapy.  In a statement, the company said the Braxia Institute plays a vital role in improving the quality of care for people receiving psychedelic drug treatments, including ketamine and esketamine therapy, for depression and related mental health disorders.  Through its research-backed training programs, the Braxia Institute is focused on advancing the knowledge base of psychiatrists, physicians, and other health care professionals globally to close the gap between clinical practice groups around the world and the protocols, competencies, and best practices identified through peer-reviewed published research.   READ: Braxia Scientific opens first ketamine therapy clinic in Quebec Braxia said it will also ensure the standard of care and protocols will be delivered across all of its clinics. CEO Dr Roger McIntyre, who is leading the institute, is widely regarded as one of the world's most recognized psychiatrists in relation to depression and associated mood disorders, as supported by research ratings by Clarivate Analytics and Expertscape, and other institute faculty members. Meanwhile, the company said that more than 200 healthcare providers from North American and Asia will be attending virtually Braxia’s first symposium on the assessment and treatment of patients with rapid-acting anti-depressants, or RAAD, such as ketamine and esketamine, and psychedelics.  "With Braxia Scientific's knowledge base, we have a tremendous opportunity to radically improve the quality of care patients receive,” Dr McIntyre said. “Braxia Scientific will play a vital role in translating and implementing the latest research for psychedelic, ketamine and esketamine therapies for persons with depression and related disorders. It is additionally our intention to inform professional standards of practice as it relates to the implementation and reimbursement of ketamine and psychedelics across private and public sectors." By focusing on research-backed education and training programs, Braxia said it is answering the call to address the growing, unmet need for accessible, high-quality, and advanced mental health services to patients diagnosed with depression, other mental health disorders, and those at risk for suicide. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham